Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-Long-Evans-Tokushima Fatty rats

Masanobu Kaihara, Yoshio Nakamura, Taro Sugimoto, Haruhito Adam Uchida, Hisanao Norii, Yoshihisa Hanayama, Hirofumi Makino

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We investigated the impact of olmesartan and temocapril on pancreatic islet β-cells during the development of diabetes mellitus using Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats. Four-week-old male OLETF rats were fed standard chow (untreated: n = 5), or chow containing either 0.005% olmesartan (n = 5) or 0.01 % temocapril (n = 5) until being sacrificed at 35 weeks of age. Pancreas sections were double-stained with anti-insulin and anti-glucagon antibodies. The percent areas of β-cells, α-cells and non-α-non-β-cells were compared among groups. In untreated OLETF rats, the fasting plasma glucose (FPG) level was elevated at the 18th week and remained elevated until the 35th week. On the other hand, no significant elevation in FPG levels was observed in olmesartan- or temocapril-treated rats. Pancreatic islets from olmesartan-treated rats were significantly smaller in size as compared with those from untreated OLETF rats. Furthermore, the average area occupied by α-cells as a fraction of the total area of an individual islet was significantly higher in olmesartan- or temocapril-treated rats than that in untreated OLETF rats. Olmesartan and temocapril both prevented the development of hyperglycemia, possibly through the prevention of islet β-cell loss in spontaneously diabetic OLETF rats.

Original languageEnglish
Pages (from-to)35-42
Number of pages8
JournalActa Medica Okayama
Volume63
Issue number1
Publication statusPublished - Feb 2009

Fingerprint

Inbred OLETF Rats
Islets of Langerhans
Hyperglycemia
Deterioration
Rats
Fasting
Glucose
Glucagon
Plasmas
olmesartan
temocapril hydrochloride
Pancreas
Anti-Idiotypic Antibodies
Diabetes Mellitus
Insulin
Medical problems

Keywords

  • Angiotensin converting enzyme inhibitor
  • Angiotensin II type-1 receptor blocker
  • Insulin secretion
  • Pancreas
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-Long-Evans-Tokushima Fatty rats. / Kaihara, Masanobu; Nakamura, Yoshio; Sugimoto, Taro; Uchida, Haruhito Adam; Norii, Hisanao; Hanayama, Yoshihisa; Makino, Hirofumi.

In: Acta Medica Okayama, Vol. 63, No. 1, 02.2009, p. 35-42.

Research output: Contribution to journalArticle

@article{61613a3d92a34f81b53edc40047533ed,
title = "Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-Long-Evans-Tokushima Fatty rats",
abstract = "We investigated the impact of olmesartan and temocapril on pancreatic islet β-cells during the development of diabetes mellitus using Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats. Four-week-old male OLETF rats were fed standard chow (untreated: n = 5), or chow containing either 0.005{\%} olmesartan (n = 5) or 0.01 {\%} temocapril (n = 5) until being sacrificed at 35 weeks of age. Pancreas sections were double-stained with anti-insulin and anti-glucagon antibodies. The percent areas of β-cells, α-cells and non-α-non-β-cells were compared among groups. In untreated OLETF rats, the fasting plasma glucose (FPG) level was elevated at the 18th week and remained elevated until the 35th week. On the other hand, no significant elevation in FPG levels was observed in olmesartan- or temocapril-treated rats. Pancreatic islets from olmesartan-treated rats were significantly smaller in size as compared with those from untreated OLETF rats. Furthermore, the average area occupied by α-cells as a fraction of the total area of an individual islet was significantly higher in olmesartan- or temocapril-treated rats than that in untreated OLETF rats. Olmesartan and temocapril both prevented the development of hyperglycemia, possibly through the prevention of islet β-cell loss in spontaneously diabetic OLETF rats.",
keywords = "Angiotensin converting enzyme inhibitor, Angiotensin II type-1 receptor blocker, Insulin secretion, Pancreas, Type 2 diabetes mellitus",
author = "Masanobu Kaihara and Yoshio Nakamura and Taro Sugimoto and Uchida, {Haruhito Adam} and Hisanao Norii and Yoshihisa Hanayama and Hirofumi Makino",
year = "2009",
month = "2",
language = "English",
volume = "63",
pages = "35--42",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-Long-Evans-Tokushima Fatty rats

AU - Kaihara, Masanobu

AU - Nakamura, Yoshio

AU - Sugimoto, Taro

AU - Uchida, Haruhito Adam

AU - Norii, Hisanao

AU - Hanayama, Yoshihisa

AU - Makino, Hirofumi

PY - 2009/2

Y1 - 2009/2

N2 - We investigated the impact of olmesartan and temocapril on pancreatic islet β-cells during the development of diabetes mellitus using Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats. Four-week-old male OLETF rats were fed standard chow (untreated: n = 5), or chow containing either 0.005% olmesartan (n = 5) or 0.01 % temocapril (n = 5) until being sacrificed at 35 weeks of age. Pancreas sections were double-stained with anti-insulin and anti-glucagon antibodies. The percent areas of β-cells, α-cells and non-α-non-β-cells were compared among groups. In untreated OLETF rats, the fasting plasma glucose (FPG) level was elevated at the 18th week and remained elevated until the 35th week. On the other hand, no significant elevation in FPG levels was observed in olmesartan- or temocapril-treated rats. Pancreatic islets from olmesartan-treated rats were significantly smaller in size as compared with those from untreated OLETF rats. Furthermore, the average area occupied by α-cells as a fraction of the total area of an individual islet was significantly higher in olmesartan- or temocapril-treated rats than that in untreated OLETF rats. Olmesartan and temocapril both prevented the development of hyperglycemia, possibly through the prevention of islet β-cell loss in spontaneously diabetic OLETF rats.

AB - We investigated the impact of olmesartan and temocapril on pancreatic islet β-cells during the development of diabetes mellitus using Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats. Four-week-old male OLETF rats were fed standard chow (untreated: n = 5), or chow containing either 0.005% olmesartan (n = 5) or 0.01 % temocapril (n = 5) until being sacrificed at 35 weeks of age. Pancreas sections were double-stained with anti-insulin and anti-glucagon antibodies. The percent areas of β-cells, α-cells and non-α-non-β-cells were compared among groups. In untreated OLETF rats, the fasting plasma glucose (FPG) level was elevated at the 18th week and remained elevated until the 35th week. On the other hand, no significant elevation in FPG levels was observed in olmesartan- or temocapril-treated rats. Pancreatic islets from olmesartan-treated rats were significantly smaller in size as compared with those from untreated OLETF rats. Furthermore, the average area occupied by α-cells as a fraction of the total area of an individual islet was significantly higher in olmesartan- or temocapril-treated rats than that in untreated OLETF rats. Olmesartan and temocapril both prevented the development of hyperglycemia, possibly through the prevention of islet β-cell loss in spontaneously diabetic OLETF rats.

KW - Angiotensin converting enzyme inhibitor

KW - Angiotensin II type-1 receptor blocker

KW - Insulin secretion

KW - Pancreas

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=62249130886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62249130886&partnerID=8YFLogxK

M3 - Article

C2 - 19247421

AN - SCOPUS:62249130886

VL - 63

SP - 35

EP - 42

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -